成分股Verve Therapeutics收跌34.95%表现最差，该公司介绍PCSK9项目的情况，宣布暂停针对高胆固醇疗法的基因编辑试验、将暂停为HEART-1临床试验招募受试对象，预计现金仍然能维持运作至2026年后期，该公司称，正调查实验室关乎安全的诸多异常现象；

华尔街见闻04-03

成分股Verve Therapeutics收跌34.95%表现最差，该公司介绍PCSK9项目的情况，宣布暂停针对高胆固醇疗法的基因编辑试验、将暂停为HEART-1临床试验招募受试对象，预计现金仍然能维持运作至2026年后期，该公司称，正调查实验室关乎安全的诸多异常现象；Biomea Fusion、Sana Biotechnology、Zentalis Pharma跌16.34%-10.54%，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2424009497?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-03 05:51","share_image_url":"https://static.laohu8.com/cc96873d3d23ee6ac10685520df9c100","id":"2424009497","market":"sh","top_or_hot":-1,"title":"成分股Verve Therapeutics收跌34.95%表现最差，该公司介绍PCSK9项目的情况，宣布暂停针对高胆固醇疗法的基因编辑试验、将暂停为HEART-1临床试验招募受试对象，预计现金仍然能维持运作至2026年后期，该公司称，正调查实验室关乎安全的诸多异常现象；","media":"华尔街见闻","content":"<div>\n<p>成分股Verve Therapeutics收跌34.95%表现最差，该公司介绍PCSK9项目的情况，宣布暂停针对高胆固醇疗法的基因编辑试验、将暂停为HEART-1临床试验招募受试对象，预计现金仍然能维持运作至2026年后期，该公司称，正调查实验室关乎安全的诸多异常现象；Biomea Fusion、Sana Biotechnology、Zentalis Pharma跌16.34%-10.54%，...</p>\n\n<a href=\"https://wallstreetcn.com/live/a-stock\">网页链接</a>\n\n</div>\n","source":"live_wallstreetcn","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7x24快讯</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7x24快讯\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-03 05:51 北京时间&nbsp;&nbsp;&nbsp;<a href=https://wallstreetcn.com/live/a-stock><strong>华尔街见闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>成分股Verve Therapeutics收跌34.95%表现最差，该公司介绍PCSK9项目的情况，宣布暂停针对高胆固醇疗法的基因编辑试验、将暂停为HEART-1临床试验招募受试对象，预计现金仍然能维持运作至2026年后期，该公司称，正调查实验室关乎安全的诸多异常现象；Biomea Fusion、Sana Biotechnology、Zentalis Pharma跌16.34%-10.54%，...</p>\n\n<a href=\"https://wallstreetcn.com/live/a-stock\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VERV","symbol_name":"Verve Therapeutics","start_time":0,"source_url":"https://wallstreetcn.com/live/a-stock","article_id":"2424009497","we_media_id":null,"thumbnails":[],"rights":{"source":"live_wallstreetcn","url":"https://wallstreetcn.com/live/a-stock","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2424009497","pubTimestamp":1712094670,"sourceInfo":{"source_id":"live_wallstreetcn","name":"华尔街见闻"},"weMediaInfo":null,"summary":"成分股Verve Therapeutics收跌34.95%表现最差，该公司介绍PCSK9项目的情况，宣布暂停针对高胆固醇疗法的基因编辑试验、将暂停为HEART-1临床试验招募受试对象，预计现金仍然能维","collect":0,"end_time":0,"defaultTopTitle":"wallstreetcn.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"VERV":"Verve Therapeutics","AMRN":"阿玛琳","LENZ":"Therapeutics","BK4585":"ETF&股票定投概念","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","BK1583":"高瓴概念","BK4139":"生物科技","SIGA":"SIGA Technologies Inc","BMEA":"Biomea Fusion, Inc.","BK4007":"制药","BK4539":"次新股","SANA":"Sana Biotechnology, Inc.","03347":"泰格医药","BK4583":"猴痘概念"},"translate_title":"Constituent stock Verve Therapeutics closed down 34.95% and performed the worst. The company introduced the situation of the PCSK9 project, announced the suspension of gene editing trials for high cholesterol therapy, and will suspend the recruitment of subjects for the HEART-1 clinical trial. It is expected that cash will still be able to maintain operations until late 2026, the company said it was investigating many abnormalities related to laboratory safety;","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03347":1,"AMRN":1,"BMEA":1,"LENZ":1,"SANA":1,"SIGA":1,"VERV":1},"content_text":"成分股Verve Therapeutics收跌34.95%表现最差，该公司介绍PCSK9项目的情况，宣布暂停针对高胆固醇疗法的基因编辑试验、将暂停为HEART-1临床试验招募受试对象，预计现金仍然能维持运作至2026年后期，该公司称，正调查实验室关乎安全的诸多异常现象；Biomea Fusion、Sana Biotechnology、Zentalis Pharma跌16.34%-10.54%，Nautilus Biotechnology也跌9.67%；Roivant Sciences则收涨4.70%，SIGA Tech涨9.78%，阿玛琳（AMRN）涨12.24%领跑。","kind":null,"is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2424009497"}